YD Bio (YDES) Common Equity (2024 - 2025)
YD Bio (YDES) posted quarterly Common Equity of -$2855.7 billion for Q4 2025, down 143.33% year-over-year from $6590.2 billion in Q4 2024, and down 56123886.42% quarter-over-quarter from $5.1 million in Q2 2025.
YD Bio (YDES) Common Equity (2024 - 2025) Analysis & Trends
YD Bio (YDES) has reported Common Equity for 2 consecutive years, with -$2855.7 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Common Equity fell 143.33% year-over-year to -$2855.7 billion; the TTM figure through Dec 2025 stood at -$2855.7 billion (down 143.33% YoY), while the FY2025 annual figure was -$2855.7 billion, down 143.33% from the prior year.
- Common Equity retreated to -$2855.7 billion in Q4 2025 per YDES's latest filing, from $5.1 million in the prior quarter.
- Across five years, Common Equity topped out at $6590.2 billion in Q4 2024 and bottomed at -$2855.7 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.29 Bn | 132.43 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.58 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.87 Bn | 56.73 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.90 Bn | 10.51 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 9.79 Bn |
| 10 | YD Bio | 311.24 Mn | 305.23 Mn | - | -2,855.66 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2,855.66 Bn |
| Jun 30, 2025 | 5.09 Mn |
| Dec 31, 2024 | 6,590.25 Bn |